Epibatidine的全合成研究进展

概述了Ｅｐｉｂａｔｉｄｉｎｅ全合成研究的进展,全文分四部分：（１）Ｅｐｉｂａｔｉｄｉｎｅ的发现和结构的确定。（２）Ｅｐｉｂａｔｉｄｉｎｅ的全合成研究;（３）氮杂双环的合成,（４）Ｅｐｉｂａｔｉｄｉｎｅ的全合成研究进展,参考文献３４篇。     

2种苯并吡喃类查尔酮天然产物的全合成

2种苯并吡喃类查尔酮天然产物的全合成;全合成;苯并吡喃类查尔酮;三羟基苯乙酮;柠檬醛;苯甲醛     

大环二萜天然产物(±)-Sinulariol-A的全合成

以香叶醇为起始原料,经多步反应完成了西松烷型大环二萜类天然产物(±)-Sinulariol-A的全合成.合成的关键步骤是醛5与丙烯酸甲酯经改进的Morita-Baylis-Hillman加成以及二价铬诱导的烯丙基氯化物与醛的分子内加成环化     

抗HIV天然产物Calanolide A及其类似物的合成进展

Calanolide A是从藤黄科红厚壳属植物(Calophyllum lanigerum)中分离的一种吡喃型香豆素类化合物, 对HIV-1- RT有很强的抑制作用, 是目前抗HIV的热点先导物. 综述了该化合物及其类似物的全合成研究进展, 分析了它的合成路线, 讨论了各合成方法的优缺点.     

（±）-13-羟基-8（14）-松香烯的全合成

（±）-13-羟基-8（14）-松香烯的全合成;三环二萜;全合成;（±） 羟基 松香烯     

Cortistatin类型天然产物的不对称形式全合成:金催化串联Semi-Pinacol重排反应策略

本工作详细报道了Cortistatin类型天然产物不对称形式全合成的研究路线.以近期作者发展的金催化串联semi-pinacol重排反应构建[3,2,1]七元氧桥环结构的方法学为基础,进一步将其应用于复杂体系,高效构建了Cortistatin类型天然产物独特的七元氧桥环核心骨架,从而完成了该类型天然产物的不对称形式全合成.     

奥利司他的全合成研究进展

综述了减肥药物奥利司他的全合成的研究进展. 根据合成策略上的不同, 将全合成研究分三部分进行了概述.     

奎宁的全合成

介绍治疗疟疾的特效药奎宁150年的全合成史和长达90年的与奎宁合成相关疑案的最终解答。     

天然产物Modhephene的全合成研究进展

综述了近年来天然产物Modhephene的全合成方法,并依据其不同的环化方法分为两大类,对每例合成方法进行了详尽的分析。     

[4 1]及[3 2]会聚式四氢呋喃环合成策略在天然产物全合成中的应用进展

四氢呋喃环广泛存在于具有生物活性的天然产物结构当中,立体选择性地构筑四氢呋喃环往往成为这些天然产物全合成研究中的关键。本文归纳了已有全合成报道中的四氢呋喃环成环策略,以实例展示了其中的会聚式合成策略在近年的发展。相比于直线型的分子内关环策略,以[4+1]、[3+2]为代表的会聚式四氢呋喃关环策略往往能够使全合成的整体路线更加简洁高效,更符合全合成研究领域的发展趋势。     

Microcalorimetry investigation of synthetic hemoprotein (albumin‐heme)

Recombinant human serum albumin (rHSA) incorporating the iron(II) complex of the tetraphenylporphyrin derivative (FepivP or FecycP) is a synthetic O₂‐carrying hemoprotein [albumin‐heme (rHSA‐FepivP or rHSA‐FecycP)], which acts as a red blood cell substitute. The association and dissociation behavior of FepivP and FecycP with rHSA has been initially investigated by isothermal titration calorimetry. A strong heat release appeared after the injection of albumin‐heme into a large molar excess of rHSA. This exothermic enthalpy change was due to the transference of hemes to the other free albumins. The difference in the heme binding affinity to rHSA can be manifested in the enthalpy term. Copyright © 2003 John Wiley & Sons, Ltd.     

Human Serum Albumin Hybrid Incorporating Synthetic Hemes:A Novel O_2-Carrying Hemoprotein

It has long been known that homologous blood transfusion will result in a lot ofserious problems such as viral infections,for example AIDS,hepatitis,antigenicsensitization and GVHD;therefore aggressive testing of donor blood has beenadopted[1 ,2 ] .Even after this introduction,which is time-consuming and expensive,wecould not eliminate all the risks. In the wake of these kinds of pitfalls,production andclinical use of the blood substitutes have emerged.The essential aim of blood substitutei…     

Heme Pocket Architecture in Human Serum Albumin: Regulation of O2 Binding Affinity of a Prosthetic Heme Group by Site-Directed Mutagenesis

Summary : We present the O₂ binding properties of recombinant human serum albumin (rHSA) mutants complexed with an iron(II) protoporphyrin IX as a prosthetic heme group. Iron(III) protoporphyrin IX (hemin) is bound within subdomain IB of HSA with weak axial coordination by Tyr-161. In order to confer O₂ binding capability to this naturally occurring hemoprotein: (i) a proximal histidine was introduced into position Ile-142; and (ii) the coordinated Tyr-161 was replaced with hydrophobic Leu using site-directed mutagenesis. It provided a recombinant HSA double-mutant [rHSA(I142H/Y161L) = rHSA(HL)]. The rHSA(HL)–heme formed a ferrous five-coordinate high-spin complex with axial ligation of His-142 under an Ar atmosphere. This artificial hemoprotein binds O₂ at room temperature. Laser flash photolysis experiments demonstrated that O₂ rebinidng to rHSA(HL)–heme displays monophasic kinetics, whereas the CO recombination process obeyed a double-exponential pattern. This might be attributable to the two different geometries of the axial imidazole coordination arising from the two orientations of the porphyrin plane in the heme pocket. The O₂ binding affinity of rHSA(HL)–heme was considerably lower than those of R-state hemoglobin (Hb) and myoglobin (Mb), principally because of the high O₂ dissociation rate constant. The third mutations have been introduced into the distal side of the heme (at position Leu-185 or Arg-186) to increase the O₂ binidng affinity. The rHSA(HL/L185N)–heme showed high O₂ binding affinity ( : 1 Torr), which is 18-fold greater than that of the original double mutant rHSA(HL)–heme and which is rather close to those of Hb (R-state) and Mb. Furthermore, replacement of polar Arg-186 with Leu or Phe adjusted the O₂ binding affinity ( ) to 10 Torr, which is almost equivalent to value for human red blood cells.     

Genetic engineering of the heme pocket in human serum albumin: modulation of O2 binding of iron protoporphyrin IX by variation of distal amino acids

Complexing an iron protoporphyrin IX into a genetically engineered heme pocket of recombinant human serum albumin (rHSA) generates an artificial hemoprotein, which can bind O2 in much the same way as hemoglobin (Hb). We previously demonstrated a pair of mutations that are required to enable the prosthetic heme group to bind O2 reversibly: (i) Ile-142-->His, which is axially coordinated to the central Fe2+ ion of the heme, and (ii) Tyr-161-->Phe or Leu, which makes the sixth coordinate position available for ligand interactions [I142H/Y161F (HF) or I142H/Y161L (HL)]. Here we describe additional new mutations designed to manipulate the architecture of the heme pocket in rHSA-heme complexes by specifically altering distal amino acids. We show that introduction of a third mutation on the distal side of the heme (at position Leu-185, Leu-182, or Arg-186) can modulate the O2 binding equilibrium. The coordination structures and ligand (O2 and CO) binding properties of nine rHSA(triple mutant)-heme complexes have been physicochemically and kinetically characterized. Several substitutions were severely detrimental to O2 binding: for example, Gln-185, His-185, and His-182 all generated a weak six-coordinate heme, while the rHSA(HF/R186H)-heme complex possessed a typical bis-histidyl hemochrome that was immediately autoxidized by O2. In marked contrast, HSA(HL/L185N)-heme showed very high O2 binding affinity (P1/2O2 1 Torr, 22 degrees C), which is 18-fold greater than that of the original double mutant rHSA(HL)-heme and very close to the affinities exhibited by myoglobin and the high-affinity form of Hb. Introduction of Asn at position 185 enhances O2 binding primarily by reducing the O2 dissociation rate constant. Replacement of polar Arg-186 with Leu or Phe increased the hydrophobicity of the distal environment, yielded a complex with reduced O2 binding affinity (P1/2O2 9-10 Torr, 22 degrees C), which nevertheless is almost the same as that of human red blood cells and therefore better tuned to a role in O2 transport.     

O2 and CO binding properties of artificial hemoproteins formed by complexing iron protoporphyrin IX with human serum albumin mutants

The binding properties of O2 and CO to recombinant human serum albumin (rHSA) mutants with a prosthetic heme group have been physicochemically and kinetically characterized. Iron(III) protoporphyrin IX (hemin) is bound in subdomain IB of wild-type rHSA [rHSA(wt)] with weak axial coordination by Tyr-161. The reduced ferrous rHSA(wt)-heme under an Ar atmosphere exists in an unusual mixture of four- and five-coordinate complexes and is immediately autoxidized by O2. To confer O2 binding capability on this naturally occurring hemoprotein, a proximal histidine was introduced into position Ile-142 or Leu-185 by site-directed mutagenesis. A single mutant (I142H) and three double mutants (I142H/Y161L, I142H/Y161F, and Y161L/L185H) were prepared. Both rHSA(I142H/Y161L)-heme and rHSA(I142H/Y161F)-heme formed ferrous five-N-coordinate high-spin complexes with axial ligation of His-142 under an Ar atmosphere. These artificial hemoproteins bind O2 at room temperature. Mutation at the other side of the porphyrin, Y161L/L185H, also allowed O2 binding to the heme. In contrast, the single mutant rHSA(I142H)-heme could not bind O2, suggesting that removal of Y161 is necessary to confer reversible O2 binding. Laser flash photolysis experiments showed that the kinetics of CO recombination with the rHSA(mutant)-heme were biphasic, whereas O2 rebinding exhibited monophasic kinetics. This could be due to the two different geometries of the axial imidazole coordination arising from the two orientations of the porphyrin plane in the heme pocket. The O2 binding affinities of the rHSA(mutant)-heme were significantly lower than those of hemoglobin and myoglobin, principally due to the high O2 dissociation rates. Changing Leu-161 to Phe-161 at the distal side increased the association rates of both O2 and CO, which resulted in enhanced binding affinity.     

Artificial cells in medicine and biotechnology

Since the feasibility of artificial cells was first demonstrated in 1957 [Chang (1, 2)], an increasing number of approaches to their preparation and use have become available. Thus artificial cell membranes can now be formed using a variety of synthetic or biological materials to produce desired variations in their permeability, surface properties, and blood compatibility. Almost any material can be included within artificial cells. These include enzyme systems, cell extracts, biological cells, magnetic materials, isotopes, antigens, antibodies, vaccines, hormones, adsorbents, and others. Since cells are the fundamental units of living organisms, it is not surprising that artificial cells can have a number of possible applications. This is especially so since artificial cells can be “tailor-made” to have very specialized functions. A number of potential applications suggested earlier have now reached a developmental stage appropriate for clinical trial or application. These clinical applications include the use of such cells as a red blood cell substitute, in hemoperfusion, in an artifical kidney or artificial liver, as detoxifiers, in an artificial pancreas, and so on. Artificial red blood cells based on lipid-coated fluorocarbon or crosslinked hemoglobin are being investigated in a number of centers. The principle of the artificial cells is also being used in biotechnology to immobilize enzymes and cells. Developments in biotechnology have also resulted in the use of the principle underlying the artificial cell to help produce interferons and monoclonal antibodies; to create immunosorbents; to develop an artificial pancreas; and to bring enzyme technology usefully into biotechnology and biomedical applications. Artificial cells are also being used as drug delivery systems based on slow release, on magnetic target delivery, on biodegradability, on liposomes, or other approaches. The present status and recent advances will be emphasized in this paper.     

Electrochemical Red Blood Cell Counting: One at a Time

We demonstrate that the concentration of a red blood cell solution under physiological conditions can be determined by electrochemical voltammetry. The magnitude of the oxygen reduction currents produced at an edge‐plane pyrolytic graphite electrode was diagnosed analytically at concentrations suitable for a point‐of‐care test device. The currents could be further enhanced when the solution of red blood cells was exposed to hydrogen peroxide. We show that the enhanced signal can be used to detect red blood cells at a single entity level. The method presented relies on the catalytic activity of red blood cells towards hydrogen peroxide and on surface‐induced haemolysis. Each single cell activity is expressed as current spikes decaying within a few seconds back to the background current. The frequency of such current spikes is proportional to the concentration of cells in solution.     

On the possibility of in vitro estimation of physiological activities of pharmaceutical drugs containing the same active ingredient

We studied whether the physiological activities of several pharmaceutical products containing the same active ingredient (pantoprazole) can be estimated by the ealier proposed method, which is based on the study of drug effect on the structures of cell membranes (red blood cells, lymphocytes, and platelets) using ESR spectroscopy and spin probes. The properties of one innovator drug and four corresponding generics were compared. There are possible cases when the innovator drug has a higher effect on the structures of blood cell membranes than generics and when the pharmaceutical products have no any effect thereon. In the latter case, the number of side effects is assumed to be minimized.

     

补充富硒小麦和富硒玉米对大鼠血硒状态影响的对比观察

给克山病病区粮喂养６周的大鼠补充富硒小麦或富硒玉米,观察了大鼠血硒和血ＣＳＨ－Ｐｘ活性的变化。结果显示,补充富硒小麦和富硒玉米均可有效地升高大鼠血浆硒、红细胞硒和红细胞ＧＳＰ－Ｐｘ活性,且两种形式硒的作用效果相同;停止补硒后,补充富硒小麦组大鼠的红细胞和红细胞ＧＳＨ－Ｐｘ活性均显著高于补充富硒玉米组大鼠。表明给大鼠补充富硒小麦较补充富硒玉米好。     

Polymer/hemoglobin assemblies: biodegradable oxygen carriers for artificial red blood cells

In routine clinical procedures, blood transfusion is now suffering from the defects of the blood products, like cross-matching, short storage time and virus infection. Various blood substitutes have been designed by researchers through continual efforts. With recent progress in nanotechnology, new types of artificial red blood cells with cellular structure are available. This article aims to describe some artificial red blood cells which encapsulate or conjugate hemoglobin molecules through various approaches, especially the nanoscale self-assembly technique, to mitigate the adverse effects of free hemoglobin molecules. These types of artificial red blood cell systems, which make use of biodegradable polymers as matrix materials, show advantages over the traditional types.